Aramco’s Prosperity7 Ventures leads China’s Cispoly $14 million Series B round 

Share via:

The Asian startup scene has seen a recent boom in investments from the Middle East. Cispoly, a China-based producer of gynecological tumor detection equipment, is one of them.

The startup has raised over 100 million yuan (US$14 million) in series B funding. Prosperity7 Ventures, the diversified growth fund of Saudi Arabian energy giant Aramco, led the round, with participation from existing investor Sunland Fund.

Established in 2020 by Liu Pei, Cispoly develops methylation detection tools for early-stage gynecological tumors – including cervical cancer, ovarian cancer, and endometrial cancer – as well as products for women’s reproductive microbiota testing.

Ciscer, Cispoly’s flagship product for real-time cervical cancer detection, was approved by China’s National Medical Products Administration in March, the company said. Upcoming products include Cisendo, an endometrial cancer screening solution – currently in clinical trials – and Cisova, which detects methylation for ovarian cancer diagnosis and is nearing clinical testing.

Cispoly will use the series B funds for R&D and global expansion, and to expedite product registrations. The startup has recently started research projects in China, with plans to expand into Southeast Asia and Europe through partnerships with medical institutions.

This isn’t Prosperity7 Ventures’ first investment in a Chinese healthtech startup. It has previously backed Fourier Intelligence, which makes exoskeleton robotics products for rehab exercise, in its series C and D rounds.

The fund’s other investments include a US$28.7 million series B round in China’s Jiandanxinli and US$35 million in Hong Kong’s Insilico Medicine last year.

Source: Wamda

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We StartupNews.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It’s possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.

Popular

More Like this

Aramco’s Prosperity7 Ventures leads China’s Cispoly $14 million Series B round 

The Asian startup scene has seen a recent boom in investments from the Middle East. Cispoly, a China-based producer of gynecological tumor detection equipment, is one of them.

The startup has raised over 100 million yuan (US$14 million) in series B funding. Prosperity7 Ventures, the diversified growth fund of Saudi Arabian energy giant Aramco, led the round, with participation from existing investor Sunland Fund.

Established in 2020 by Liu Pei, Cispoly develops methylation detection tools for early-stage gynecological tumors – including cervical cancer, ovarian cancer, and endometrial cancer – as well as products for women’s reproductive microbiota testing.

Ciscer, Cispoly’s flagship product for real-time cervical cancer detection, was approved by China’s National Medical Products Administration in March, the company said. Upcoming products include Cisendo, an endometrial cancer screening solution – currently in clinical trials – and Cisova, which detects methylation for ovarian cancer diagnosis and is nearing clinical testing.

Cispoly will use the series B funds for R&D and global expansion, and to expedite product registrations. The startup has recently started research projects in China, with plans to expand into Southeast Asia and Europe through partnerships with medical institutions.

This isn’t Prosperity7 Ventures’ first investment in a Chinese healthtech startup. It has previously backed Fourier Intelligence, which makes exoskeleton robotics products for rehab exercise, in its series C and D rounds.

The fund’s other investments include a US$28.7 million series B round in China’s Jiandanxinli and US$35 million in Hong Kong’s Insilico Medicine last year.

Source: Wamda

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We StartupNews.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It’s possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.

Website Upgradation is going on for any glitch kindly connect at office@startupnews.fyi

More like this

OneRail’s software helps solve the last-mile delivery problem

Last-mile delivery, the very last step of the...

Bill to ban social media use by under-16s arrives...

Legislation to ban social media for under 16s...

TBO Tek Wins INR 30.2 Cr Service Tax Case,...

SUMMARY CESTAT ruled in favour of TBO Tek, setting...

Popular

Upcoming Events

Startup Information that matters. Get in your inbox Daily!